$0.740
-0.018 (-2.49%)收盘时
BRNS 同业对比
In the context of the broader market, BRNS competes directly with industry leaders such as BYSI and ABVC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against BYSI's N/A and ABVC's N/A. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
Barinthus Biotherapeutics PLC 财务表现
The company reported total revenue of $14.97 million in Q3 2024 but has faced significant net losses, including -$10.58 million in Q2 2026. The gross margin is currently at 100% for Q3 2024, but this is not sustainable as revenue has dropped to zero in subsequent quarters.
Financials
相关文章
- Equal-Weight vs Cap-Weighted S&P 500: RSP vs SPY After October's Rotation and Nvidia's CEO ShockEqual weight vs cap weighted S&P 500: how RSP and SPY differ, why October 2026's rotation was the widest since 2009, and how to blend both after Nvidia's shock.
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。